Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01832727 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT01832727 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 65 participants.
The verdict
NCT01832727, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary objectives are: Phase 1b: * To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules. * To evaluate safety and tolerability Phase 2: * To estimate the overall response rate (ORR). * To evaluate safety and tolerability
Interventions
- DRUG Dexamethasone
- DRUG Oprozomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2013-07-02 |
| Est. Completion | 2019-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01832727
The ClinicalTrials.gov registry entry for NCT01832727 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01832727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01832727 about?
NCT01832727 is a clinical study titled "Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma". The primary objectives are: Phase 1b: * To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules. * To evaluate safety and tolerability Phase 2: * To estimate the overall response rate (ORR). * To evaluate s...
What is the current status of trial NCT01832727?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2013-07-02. Estimated completion is 2019-06-25.
What interventions are being tested in trial NCT01832727?
The interventions under investigation include: Dexamethasone (DRUG), Oprozomib (DRUG).
Who is sponsoring clinical trial NCT01832727?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.